Holen Sie sich die Stockscreener-App
137.99
3.35%
-4.78
Handel nachbörslich:
136.53
-1.46
-1.06%
Schlusskurs vom Vortag:
$142.77
Offen:
$137.19
24-Stunden-Volumen:
26.18M
Relative Volume:
2.18
Marktkapitalisierung:
$55.09B
Einnahmen:
$2.23B
Nettoeinkommen (Verlust:
$-3.19B
KGV:
-16.94
EPS:
-8.1462
Netto-Cashflow:
$-1.60B
1W Leistung:
-4.92%
1M Leistung:
+147.27%
6M Leistung:
+157.59%
1J Leistung:
+463.91%
1-Tages-Spanne:
$133.33
$138.80
1-Wochen-Bereich:
$130.00
$161.37
52-Wochen-Spanne:
$22.28
$176.66
Moderna Inc Stock (MRNA) Company Profile
Firmenname
Moderna Inc
Sektor
Branche
Telefon
(617) 714-6500
Adresse
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
137.99 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
VRTX
Vertex Pharmaceuticals Inc
|
541.69 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
794.19 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,023.21 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
207.88 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Fortgesetzt | Barclays | Equal Weight |
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-12 | Eingeleitet | Jefferies | Hold |
| 2025-03-13 | Eingeleitet | Citigroup | Neutral |
| 2025-02-18 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Herabstufung | Goldman | Buy → Neutral |
| 2024-12-18 | Herabstufung | Argus | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Underperform |
| 2024-11-19 | Eingeleitet | Berenberg | Hold |
| 2024-11-18 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Underperform |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-09-13 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Herabstufung | Jefferies | Buy → Hold |
| 2024-09-13 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Eingeleitet | Canaccord Genuity | Hold |
| 2023-11-03 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Eingeleitet | William Blair | Mkt Perform |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-06-26 | Hochstufung | UBS | Neutral → Buy |
| 2023-04-26 | Eingeleitet | Guggenheim | Neutral |
| 2023-03-13 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-02-24 | Herabstufung | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Hochstufung | Jefferies | Hold → Buy |
| 2022-12-14 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Hochstufung | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Hochstufung | Redburn | Sell → Neutral |
| 2022-01-26 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Eingeleitet | UBS | Neutral |
| 2021-12-07 | Eingeleitet | Cowen | Market Perform |
| 2021-11-09 | Eingeleitet | Wolfe Research | Outperform |
| 2021-10-22 | Eingeleitet | Deutsche Bank | Sell |
| 2021-10-15 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Bestätigt | Jefferies | Hold |
| 2021-02-01 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Herabstufung | Jefferies | Buy → Hold |
| 2020-12-16 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Herabstufung | Needham | Buy → Hold |
| 2020-11-23 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-11-17 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-07-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Eingeleitet | Jefferies | Buy |
| 2020-06-30 | Eingeleitet | Argus | Buy |
| 2020-06-08 | Eingeleitet | Barclays | Overweight |
| 2020-04-30 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-03-05 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-10-25 | Eingeleitet | ROTH Capital | Buy |
| 2019-04-05 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Moderna Inc Aktie (MRNA) Neueste Nachrichten
Moderna cancer vaccine breakthrough revives hopes for biotech turnaround By Investing.com - Investing.com Nigeria
SLS, IBRX Stocks In Focus: Analyst Says Moderna-Merck Cancer Vaccine Success ‘Bodes Well’ For Oncology - Stocktwits
Health Care Up as Moderna Leads Biotech HigherHealth Care Roundup - marketscreener.com
Moderna Shares (NASDAQ:MRNA) Finish Landmark Week, Surging 70% Over Wall Street Consensus - TechStock²
SLS Stock Clocks Three Straight Weeks Of Gains On Cancer Vaccine Spillover, REGAL Trial Data Anticipation - Yahoo Finance
Moderna Soars 129% for the Week | Closing Bell - marketscreener.com
Moderna Stock Erupts As Cancer Vaccine Trial Delivers Historic Win - StocksToTrade
Moderna Stock Explodes As Phase 3 Cancer Vaccine Data Hits - timothysykes.com
Moderna, Robinhood, Marvell, Tesla, SpaceX, and More Stocks That Explain Today’s Market - Barron's
Bessent's Bond Rescue, Bitcoin's Best Week Since 2023Coinbase Global (NASDAQ:COIN) - Benzinga
Moderna (MRNA) Cancer Vaccine Success Won’t Lift All mRNA Stocks - Barron's
Moderna Just Doubled on a Massive Cancer Breakthrough. Here’s Why MRNA Stock Isn’t a Buy Yet. - Barchart.com
Moderna’s Cancer Vaccine Breakthrough Sends Stocks Soaring - cheddar.com
Why Moderna’s mRNA Cancer Drug Hype Has Gone Too Far - Barron's
If You Invested $1,000 In Moderna Stock at IPO, Here's How Much You'd Have Now - TradingView
Moderna Stock Explodes As Landmark Cancer Trial Sparks Re‑Rating - StocksToTrade
Moderna Stock Explodes After Landmark Cancer Vaccine Breakthrough - timothysykes.com
How a Big Bet on Cancer Vaccines Brought Moderna Back from the Brink - WSJ
Moderna (NASDAQ:MRNA) Price Target Raised to $77.00 at JPMorgan Chase & Co. - MarketBeat
After Moderna’s Big News, Here Are Three Biotechs to Watch - TheStreet Pro
Moderna Inc Stock (MRNA) Moved Up by 14.01% on Aug 21: What Signal Does It Send? - TradingKey
Moderna, Robinhood, Marvell, Tesla, SpaceX, and More Stocks That Explain Today's Market -- Barrons.com - Moomoo
Moderna jumps 18% on investor optimism - Breakingthenews.net
Moderna Options Flash Extreme Caution as Cancer Vaccine Fuels Stock Surge: Options Chatter - Moomoo
Moderna Cancer Vaccine Could Redefine the CompanyModerna (NASDAQ:MRNA) - Benzinga
Moderna (NASDAQ:MRNA) Sees Strong Trading Volume on Analyst Upgrade - MarketBeat
Merck & Co Inc Stock (MRK) Moved Up by 3.41% on Aug 21: Facts Behind the Movement - TradingKey
Moderna Rallies 8%, BioNTech Climbs 4% as the mRNA Trade Whipsaws for a Third Session - Yahoo Finance
Moderna and Merck’s cancer vaccine clears phase 3; Ultragenyx lands gene therapy nod - Pharma Voice
Moderna, Merck mRNA cancer vaccine prevents melanoma from returning in trial - KXAN Austin
Rx Rundown: Moderna, Merck, LEO Pharma and more - Medical Marketing and Media
Moderna’s 177% Surge Has Investors Asking What Comes Next - MarketBeat
Moderna’s personalized mRNA shot could reshape the fight against skin cancer — but it may also be overhyped - MarketWatch
Moderna and Merck cancer vaccine success paves way for future - EMJ
Pharma Bro Admits 'Playing Around' With MRNA Short At $80 Before it Exploded 177% Following Cancer Vax Trials— ‘I Bet You a Bunch of People Got Fired’ - Yahoo Finance
Meeder Advisory Services Inc. Buys New Shares in Moderna, Inc. $MRNA - MarketBeat
MEXC Lists Ondo Tokenized Stock Moderna (MRNAON), Expanding Access to U.S. Biotech Exposure - TradingView
A Cancer Vaccine Is Closer Than Ever - Bloomberg.com
Amid the chip bear market, healthcare is breaking out: Chart of the Day - Yahoo Finance
JPMorgan Adjusts Price Target on Moderna to $77 From $40, Keeps Underweight Rating - marketscreener.com
Elon Musk Says mRNA Has ‘Tremendous’ Potential After Moderna, Merck Cancer Vaccine Breakthrough — MRNA Stock Falls Over 11% in Premarket (UPDATED) - Yahoo Finance
Personalized cancer vaccine launched by Moderna: Drug firm’s shares soar more than 100% — should you buy? - Yahoo! Finance Canada
Mitsubishi UFJ Asset Management Co. Ltd. Acquires New Holdings in Moderna, Inc. $MRNA - MarketBeat
983,450 Shares in Moderna, Inc. $MRNA Bought by Deutsche Bank AG - MarketBeat
Moderna (MRNA) Clears A Phase 3 Milestone, Is The Upside Already Priced In? - Yahoo Finance
5 Reasons Why Moderna Stock Jumped 170% and How Far It Can Go - CryptoRank
Watch Moderna, Merck Cancer Vax Gives Hope - Bloomberg.com
Moderna, Merck develop vaccine that could help fight against melanoma - cbs8.com
Moderna (MRNA) Sees Stock Surge After Positive Melanoma Trial Re - GuruFocus
FDA approves Moderna's mRNA seasonal flu vaccineABC News - ABC News - Breaking News, Latest News and Videos
Moderna's Comeback Is Finally Taking Shape -- and There May Be More Upside Ahead - Yahoo Finance
Finanzdaten der Moderna Inc-Aktie (MRNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Moderna Inc-Aktie (MRNA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Bancel Stephane | Chief Executive Officer |
Aug 06 '26 |
Option Exercise |
19.15 |
252,469 |
4,834,781 |
6,440,260 |
| Bancel Stephane | Chief Executive Officer |
Aug 05 '26 |
Sale |
57.52 |
499,246 |
28,715,011 |
6,187,791 |
3.37%
0.23%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):